Regulatory Action
HCG Receives CDSCO Suspension Order for KR Unit Ethics Committee; Company Says No Material Impact on Operations
NSE
HCG
BSE
539787
Healthcare Global Enterprises Limited (HCG) disclosed that the Central Licensing Authority (CLA) under CDSCO has suspended the KR Unit Ethics Committee at HCG Bangalore Institute of Oncology from approving or overseeing new clinical trials and bioavailability/bioequivalence studies for 24 months. The company stated that the suspension is limited to the specific ethics committee and does not affect hospital operations, patient care, or other business units.
PRICE-SENSITIVE TRIGGER
Event: Suspension Order Issued by CDSCO to KR Unit Ethics Committee
Type: Regulatory Action
Impact: Negative
Immediate Effect:Â The Central Licensing Authority has directed the suspension of the KR Unit Ethics Committee at HCG Bangalore Institute of Oncology for a period of 24 months from approving or overseeing any new clinical trial or bioavailability/bioequivalence study. While the order impacts the committee’s ability to undertake new study approvals, HCG has clarified that the action is restricted to this specific ethics committee and does not extend to other ethics committees, hospital operations, patient care activities, or other units of the company. The company is currently reviewing the order and evaluating available legal remedies.
Key Metrics:
- No revenue impact disclosed.
- No EBITDA impact disclosed.
- No PAT impact disclosed.
- No margin impact disclosed.
- No QoQ or YoY financial impact disclosed.
- No segment-wise financial impact disclosed.
Highlight:
- Company states there is no significant impact on financial operations or business activities based on current assessment.
What Happened ?
Healthcare Global Enterprises Limited informed stock exchanges that the Central Licensing Authority (CLA), operating through the Central Drugs Standard Control Organization (CDSCO), issued a suspension order dated June 12, 2026, which was received by the company on June 16, 2026.
The order pertains to the KR Unit Ethics Committee located at HCG Bangalore Institute of Oncology, Bengaluru. The committee has been suspended from approving or overseeing new clinical trials and bioavailability/bioequivalence studies for a period of 24 months.
According to the regulatory disclosure, the suspension arises from alleged non-compliance with provisions of the New Drugs and Clinical Trials Rules, 2019. The company has stated that the order is limited to the concerned ethics committee and is currently being examined along with available legal options.
Key Details
Expansion Plan Details:
- The regulatory authority involved is the Central Licensing Authority (CLA) under CDSCO, Directorate General of Health Services, Government of India.
- Suspension applies only to the KR Unit Ethics Committee at HCG Bangalore Institute of Oncology, Bengaluru.
- The suspension period is 24 months from the date of receipt of the order.
- The committee is barred from approving or overseeing new clinical trials and BA/BE studies during the suspension period.
- Alleged violations include delays in reporting Serious Adverse Events (SAEs) to regulatory authorities.
- The order cites deficiencies in SAE reporting, SAE review documentation, conflict-of-interest disclosures, committee governance records, and participant safety oversight processes.
- The suspension does not extend to other ethics committees operating within the HCG network.
- Hospital operations and patient care activities remain unaffected according to the company.
Note:
- HCG has stated that the suspension order is currently under review and that the company is evaluating legal remedies available under applicable regulations.
Risk Analysis
Summary:
- The regulatory action creates compliance and reputational risks related to clinical research governance at the affected oncology unit. While the company has indicated no immediate operational or financial impact, prolonged restrictions on ethics committee activities could affect future clinical trial approvals at the concerned center.
Key Risks:
- Regulatory compliance concerns related to clinical trial oversight.
- Potential impact on future clinical research activities at the affected unit.
- Increased regulatory scrutiny of research governance processes.
- Reputational risk among research partners and sponsors.
- Possible delays in onboarding new clinical studies at the suspended committee.
Worst Case Scenario:
- If the suspension remains in force for the full duration and alternative regulatory arrangements are not implemented, the affected unit could face reduced participation in new clinical research programs, potentially impacting future research-related opportunities and stakeholder confidence.
Risk Level: Medium
Company Commentary
- The suspension order is addressed exclusively to the KR Unit Ethics Committee.
- The order does not affect any other ethics committee within the company.
- Hospital operations and patient care activities continue without disruption.
- Based on current assessment, the company does not expect any significant impact on financial operations or business activities.
- HCG is examining the suspension order and evaluating available legal remedies.
Official Exchange Filing: Healthcare Global Enterprises Limited
